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ABSTRACT 
 
ABSTRACT 
Photodynamic Therapy (PDT) is a minimally invasive radiation therapy currently used in 
treatment of various cancerous and pre-malignant diseases. 
Photodynamic therapy with 5-aminolaevulinic acid (5-ALA/PDT) induces DNA damage 
following photoactivation of Protoporphyrin IX (PpIX), the photosensitizer generated from 
the endogenous metabolism of 5-ALA. The occurrence of DNA damage could represent one 
of the last causes of cell death induced by PDT. 
We have dissected the molecular effectors involved in the DNA damage induced by 5-
ALA/PDT in several cell lines: 1. two lung adenocarcinoma cell lines, namely H1299 (p53
-/-
) 
and A549 wild type (p53
+/+
); 2. two sub-clones of the same cell line HCT-116, that differ for 
p53 expression (p53
+/+
 and p53
-/-
) and 3. a prostate adenocarcinoma cell line, PC3 (p53
-/-
). We 
have focused our attention on p53, which controls the DNA damage response and on the 
efflux regulator ATP binding cassette transporter G2 (ABCG2). The levels and the activity of 
these two gene products are relevant for the survival in cells exposed to photodynamic 
treatment. Cell cycle, DNA damage (phosphorylated γ-H2AX and Comet assay) and ABCG2 
levels were measured before or after irradiation. 
We found that all cell lines, except A549 and PC3, underwent extensive DNA damage upon 
PDT. The resistance of A549 and PC3 cells to photodynamic DNA damage was due to the 
high levels of ABCG2 expression upon irradiation. In fact, these cells displayed high levels of 
DNA damage signatures and underwent death when the ABCG2 was inhibited. Analysis of 
ABCG2 expression shows a complex regulation at transcriptional and post-transcriptional 
levels and its expression was dependent on oxidative stress. On the other hand, p53 
expression or activity did not exert a significant effect on 5-ALA-induced cell death. 
Taken together, all these findings provide novel information on the role of the ABCG2 
transporter in oxidative stress and a new tool to manipulate resistance to photodynamic 
therapy. 
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1. INTRODUCTION 
1.1 BACKGROUND INFORMATIONS 
Photodynamic Therapy (PDT) is a photochemistry-based therapeutic approach that requires 
the employ of a non-toxic Photosentitizers (PS), a light source specific for the selected PS and 
oxygen presents into cells’ microenvironment.  
After the systemic administration of a non-toxic PS (generally, an exogenous molecule), the 
PS accumulates in host and tumor cells (FIGURE 1). The subsequent illumination of the tumor 
site with the light source, corresponding to the specific PS absorption wavelength, excites the 
PS and leads to the generation of singlet oxygen and other reactive oxygen species (ROS), 
which caused oxidative damage to intracellular macromolecules and consequently leads cells 
to death
1
. 
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FIGURE 1. Basic principle of Photodynamic Therapy (PDT). 
Despite several advantages, Photodynamic therapy remains a marginal approach to cure 
specific types of cancers mainly because the low penetration of light into human tissues. This 
limited penetration into targeted tissue prevents the occurrence of an efficient stimulation of 
the PS in tumor lower layers except those directly illuminated (i.e. the very first, 
approximately 2 mm into the tissue which is sufficient in many cases for skin diseases) or 
those just under them. Depending on the selected PS, the effects of irradiation can reach since 
1-1,5 cm into tissue and internal solid tumors can be reached by interstitial optics fiber or 
scopes
2,3
. 
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Generally, the damage mediated by ROS occurs at the site of accumulation of the PS and cells 
death is induced by a mixture of apoptosis, necrosis and autophagy. PDT may or may not 
induce DNA damage due to ROS propagation, half life of the species generated and ability to 
cells to retain them
4
 
1.2 STORY OF PHOTODYNAMIC THERAPY 
The therapeutic properties of light were approved for clinical trials only in the last century but 
the use of the light as a treatment for diseases has a very ancient origin. In fact, it is known 
that light has been used as therapy for more than three thousand years as Egyptian, Indian and 
Chinese civilizations used light to treat various diseases, in general skin cancers
5
.  
At the beginning of the twentieth century, Niels Finsen developed “phototherapy” to treat 
diseases. He used red-light exposure to prevent the formation and release of smallpox pustules 
and the ultraviolet light from the sun to treat cutaneous tubercolosis. Such treatments 
introduces the era of the modern light therapy and, for his discoveries, Finsen won the Nobel 
prize in Physiology or Medicine in 1903
6
 (FIGURE.2).  
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FIGURE 2. Timeline of selected milestones in the historical development of PDT (2015). 
From these experiments, the therapeutic application of PDT in vivo and on patients took a 
long time. We have to wait the 1975, when T. Dougherty and his co-workers succeeded in 
completely eradicating mammary tumor growth in mice
7
. Following these preliminary 
successes, in 1999 the Food and Drug Administration (FDA) approved the first PDT drug in 
Canada. The photosensitizer was Photofrin
®
, a partially purified HpD, discovered by 
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Dougherty in 1983
8
 and also nowadays is still the most commonly used photosensitizer in 
clinical use. 
After Photofrin
®
, new photosensitizers were developed and the most common ones approved 
for clinical use are Foscan (a chlorine photosensitizer), 5-aminolevulinic acid (5-ALA, 
Levulan
®
) and 5-ALA methylesther (Metvix). 
Currently, PDT is recommended for patients with early-stage dermatological cancers that 
were inoperable and, more in general, for the treatment of non malignant, malignant and pre-
malignant diseases localized in hollow organs achievable by a light probe
1
 (TABLE 1)  
DRUG COUNTRY DISEASE
NON-MALIGNANT
Visudyne EU, USA
AMD – age-related
macular degeneration
Methylene Blue EU Periodontitis
PRE-CANCER
Levulan, Metvix EU
Actinic keratosis
Non-Melanoma skin
cancer
Photofrin EU, USA Barret’s oesophagus
Photofrin, Hexvix Japan Cervical dysplasia
CANCER
Metvix EU Basal-cell carcinoma
Photofrin;
Hexvix, Levulan
Japan Cervical cancer
Photofrin
Canada, Denmark, Finland,
France, Germany, Ireland,
Japan, The Netherlands, UK,
USA
Endobroncheal cancer
Photofrin
Canada, Denmark, Finland,
France, Ireland, Japan, The
Netherlands, UK, USA
Oesophageal cancer
Photofrin Japan Gastric cancer
Foscan EU Head and neckcancer
Photofrin Canada Papillary bladder cancer
Tookad EU Prostate cancer
Hexvix EU
Bladder cancer
(fluorescence guided
resection)
5-ALA EU, Japan
Glioblastoma
(fluorescence guided
resection)
 
TABLE 1. Types of disease and cancer treated with PDT and approved drugs (2015). 
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1.3 PRINCIPLES AND PHOTOCHEMISTRY OF PHOTODYNAMIC THERAPY 
PDT exerts its therapeutic effects through the oxygen present in the cell microenvironment. 
The photochemical reaction that generates singlet oxygen from the ground-state oxygen is 
represented by the Jablonsky diagram (FIGURE 3). 
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FIGURE 3. Jablonski diagram showing the various modes of excitation and relaxation in a photosensitizers: a. 
excitation, b. fluorescence, c. non-radiative decay, d. intersystem crossing (ISC), e. phosphorescence. 
After irradiation, the PS from the ground-state is transformed into a transient excited state. 
When it returns into its ground-state, the energy relapsed can be transformed into a 
fluorescent signal or, more interesting, can be converted into an excited triplet state via 
intersystem crossing (ISC)
9
. From this state, the PS can also return into its ground state by 
emitting a phosphorescent photon or giving rise to two types of reactions referred to as type I 
and II (FIGURE 4). 
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FIGURE 4. Schematic representation of Type I and Type II reaction in PDT. 
In type I photoreaction, the excited photosensitizer transfers one electron to a substrate 
causing the formation of radical species (radical or ion-radical), which, in the presence of 
oxygen, yield reactive oxygenated products. Alternatively, the direct transfer of the extra 
electron to oxygen generates a superoxide radical anion. In the type II reaction, the excited 
sensitizer may form excited state singlet oxygen (
1
O2) by transferring its excess energy to 
ground-state molecular oxygen. Singlet oxygen, then, reacts with the substrate to generate 
oxidized products. Generally, Type II reactions are predominant in PDT although both 
reactions can occur simultaneously inside the cells. Moreover, the photosensitizer is not 
destroyed through this process but become inactive through a photochemical process called 
photobleaching, by which the PS can be transformed into a different molecular form that does 
not absorb light
10,
 
11
. 
 
 
1.4 PHOTOSENSITIZERS IN CLINICAL PDT 
The ideal photosensitizers in clinical PDT, both of natural or synthetic origin, must have 
specific characteristics. It must not be a toxic chemical, it should be selective and should 
accumulate in those tissues where it can be useful. Its wavelength absorption must not 
interfere with other chromophores present within cells and tissues but must be also excitable 
at longer wavelengths of activation for a deeper tissue penetration. Moreover, it must have an 
easy administration, a suitable solubility in cell’s microenvironment and a high accessibility 
for target cells
12
. 
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Current available photosensitizers can be categorized into various and broad families: the 
hematoporphyrins and its derivatives (HpD), the chlorins and the dyes. 
Among these, most of the PSs used in cancer therapy are HpD and, in particular, Photofrin
®
 
(a mixture of mono-, di- and oligomers that all contain a porphyrin moiety)
 
is the most 
commonly
 
administered in fact is still nowadays used for the treatment of bladder cancer, 
esophageal cancer, early non-small cell lung cancer and Barrett's esophagus. Unfortunately, 
although it succeeded in fighting such types of cancers, there are several limitations of its use. 
First, it is composed by a mixture of about 60 compounds so its composition is difficult to 
reproduce. Moreover, high concentrations of both PS and light must be administered to the 
patients with the drawback that it is also not very selective for tumor tissue
1
.  
So, it was necessary to invest significative efforts in the development of new photosensitizers.  
 
 
1.5  5-AMINOLEVULINIC ACID: A PRODRUG FOR PDT 
5-aminolevulinic acid (5-ALA, FIGURE. 5) is not considered a PS per se due to the fact that it 
is the precursor of the natural photosensitizer protoporphyrin IX (PpIX). It is a polar molecule 
and, in physiological pH, occurs mainly as a charged zwitterion. Such characteristic account 
for its low lipid solubility and reduced bioavailability. 
H2N OH
O
O N
NH N
HN
-OOC COO-
ALA
PpIX  
FIGURE 5. 5-Aminolevulinic Acid (5-ALA), the precursor of natural PS protoporphyrin IX (PpIX). 
Once inside the cells, 5-ALA is metabolized by the heme biosynthetic pathway where in 7 
step is transformed into PpIX, the real PS. In the physiological pathway, PpIX is transformed 
into heme by the action of the enzyme ferrochelatase that binds an iron atom to PpIX to form 
heme. The production of heme exerts a normal feedback repression on the enzyme ALA 
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synthase, that is the regulatory enzyme of the all pathway
13
 (it is also important to note that 
such enzyme can be repressed not only by a direct inhibition but also by inhibiting its 
transcription, translation and transport into mitochondria
14
). It is known that, although nearly 
all human cell types are able to produce heme due to the presence of the enzymes involved in 
the synthetic pathway, a distinct activity of the enzymes in tumor leads to a higher PpIX 
accumulation within transformed cells.
15
 In fact, in such cells, there is a decreased activity of 
ferrochelatase
16, 17
, an higher activity of porphobilinogen deaminase (PBGD, that catalyzes 
the formation of uroporphyrinogen III from porphobilinogen)
14
 and a limited availability of 
iron
18
 therefore, by administering 5-ALA exogenously in large excess, an higher amount of 
PpIX accumulates inside the cells that became photosensitive (FIGURE. 6).  
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FIGURE 6. Schematic representation of heme biosynthesis in normal and transformed cells. 
Thanks to its prodrug characteristics, 5-ALA is considered a good molecule for PDT because 
represent an alternative approach to the direct administration of a PS. In fact, it is 
administered topically so it is possible to localize the treatment course without burning the 
untreated regions. 
5-ALA also presents some limits like a low lipophilicity and a scarce membrane and skin 
permeability. To this purpose, an improvement of the compound takes advantages from 
several modifications at its carboxyl termination. Until now, at least 77 various 5-ALA 
modifications have been reported. The most successful 5-ALA derivatives are its esters: 
methyl ester (methyl aminolevulinate, MAL, Metvix®) and hexyl ester (hexyl 
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aminolevulinate, HAL, Hexvix®). Elongation of a carbon chain attached to 5-ALA results in 
increased lipophilicity and, in consequence, higher membrane and skin permeability
19
. 
The very first topical application in the clinical use of 5-ALA/PDT was in 1990
19
 for the 
treatment of basal cell carcinoma and, since that moment, the use of 5-ALA/PDT is still 
growing. Nowadays, 5-ALA/PDT is an approved treatment for several cancer diseases such as 
actinic keratosis
20
, superficial bladder cancers
21
, gliomas
22
, gastric cancers
23
 and non-
melanoma skin cancer
24
. 
All these evidences make 5-ALA and its derivatives a versatile and efficient therapeutic 
strategy, with a broad field of application. 
 
 
1.6 PHOTODYNAMIC THERAPY AND DNA DAMAGE 
Compared to the other traditional cancer therapies, 5-ALA/PDT has many advantages: 1. 
lower cytotoxic mechanisms; 2. the ability to easily access the area to be treated through the 
use of light, especially in the case of tumors that invade hollow organs (by avoiding or 
reducing normal tissue damage around the treated area); 3. the reduction of long-term 
morbidity and the possibility to repeat the treatment thanks to a better patient’s compliance. 
Despite such characteristics, it is still considered a palliative therapy and is still investigated 
its role as a support for canonic therapies. In fact, the use of the light source and the low 
penetration of light limit the therapeutic applications only to the most superficial areas, or to 
the most accessible by a light probe. However, the intracellular action mediated by ROS can 
produce significant effects on the cells with a potentially significant therapeutic aspect. ROS 
have a lifetime of less than 3,5 μs and can diffuse only 0,01 to 0,02 μm during this period11. 
Due to the limited lifetime, ROS exert their cytotoxic action limited to the site of their 
localization. When they are concentrate mostly in mitochondria or endoplasmic reticulum 
(ER), cells die in an apoptotic manner while, if they are concentrate either at the plasma 
membrane or lysosomes, cells’ fate is necrosis or autophagy, respectively25, 26. Also the 
nuclear compartment can be target of ROS even if studies about DNA damage after PDT are 
still scarcely investigated
27
. It has been reported that photo activation of a HpD caused direct 
DNA damage
28
, as well as production of 8-oxo-Guanine, a typical product of DNA oxidative 
damage
29
.  
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In all probability, the reason why the nuclear compartment is not targeted by ROS is to be 
found not only in the limited half-life of the species or in the localization of the PS outside the 
nucleus but also by other effectors that may contribute to the cause. 
 
 
1.7 THE ROLE OF ABCG2 IN PHOTODYNAMIC THERAPY 
Among the other effectors that may have a role on the effectiveness of PDT, several 
evidences suggest that ABCG2 (a member of the ATP-binding cassette (ABC) transporters 
superfamily) is implicated in resistance of cancer cells to PDT. 
ABCG2 is located on chromosome 4q22 and was firstly identified as breast cancer resistant 
protein (BCRP) in doxorubicin-resistant breast cancer cells
30
. It is a so-called “half ABC 
transporter” due to the fact that is composed by six transmembrane domains and only one 
ATP-binding cassette (FIGURE 7). In humans, it exist on the plasma membrane as an 
homodimer and works mainly as exporters of endogenous materials or exogenous drugs from 
cytoplasm into extracellular environment
31
. 
 
FIGURE 7. Molecular structure of ABCG2 transporter. 
ABCG2 is expressed in the plasma membrane of placental trophoblast cells, in the epithelium 
of the small intestine, in liver canalicular membrane and in ducts and lobules of the breast. In 
all these compartments, it is involved in a protective role from toxic metabolites or in a 
regulating role of administered drugs
32
. Several studies indicate that ABCG2 over-expression 
in transformed cell lines confers resistance to many chemotherapeutic drugs so it is 
considered one of the main actors in the multi-drug resistance (MDR)
30, 33, 34
. More recently, it 
was discovered that ABCG2 is able to extrude among its substrates also PpIX so it may have 
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an important role in the PDT effectiveness
35, 36
. In fact, its over-expression is associated to a 
reduction of PpIX amount retained within the cells and, consequently, to a reduction of 5-
ALA/PDT effectiveness
37, 38
. 
The expression of ABCG2 is regulated, both in normal and cancer cells, at different levels 
including epigenetic and transcriptional modifications
31
. It is still unknown at what level the 
transporter is up-regulated in cells treated with 5-ALA/PDT due to the simultaneous effect of 
the excess of PpIX inside the cells and the ROS production. Such evidences may throw light 
on a novel aspect of ABCG2 regulation an may unravel the molecular pathway that subtend 
its over-expression. 
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2. AIMS OF THE THESIS 
The analysis of DNA damage caused by PDT contributes to a better understanding of the 
mechanism of oxidation induced DNA damage and may pave the way to improved anti-
cancer therapy. Targeted delivery of photosensitizers to the nucleus or long range propagation 
of ROS-mediated damage are essential tools to potentiate the effectiveness of PDT as tumor-
cell killing
39
. 
To this purpose, the objectives of this study are the following:  
a. to explore the biological effects of 5-ALA/PDT on a panel of five cell lines 
characterized by different levels of p53 and the ATP binding cassette G2 (ABCG2) 
transporter; 
b. to identify the molecular effectors involved in the PDT-induced DNA damage; 
c. to unravel the regulation of ABCG2 expression by oxidative stress. 
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3. MATERIAL AND METHODS 
3.1 Cell cultures 
Non-small-cell-lung-cancer cell lines H1299 (p53
-/-
) and A549 (p53
+/+
) were obtained from 
ATCC (Rockville, MD, USA). H1299 cell line was cultured in RPMI 1640 medium, 2 mM L-
glutamine, 10 mmol/l HEPES, 1 mM sodium pyruvate, 2.5 g/l glucose, 1.5 g/l sodium 
bicarbonate, 10% FCS and 1% penicillin/streptomycin; A549 cell line was cultured in F12K 
medium, 0.75 g/l sodium bicarbonate, 2 mM L-glutamine, 10% FCS and 1% 
penicillin/streptomycin.  
The colorectal HCT-116 colon cancer cells were kindly provided by B. Vogelstein
40
 and 
cultured according ATCC in complete McCoy's 5A medium, consisting of 10% fetal bovine 
serum, 1% penicillin/streptomycin and 2 mM L-Glutamine. The two lines are p53
+/+
 and p53
-/-
 
(the latter obtained by knocking out the p53 gene). The prostatic adenocarcinoma cell line 
PC3 were obtained from ATCC (Rockville, MD, USA) and cultured in RPMI, 10% FCS, 2 
mM L-glutamine and 1% penicillin/streptomycin. Saline solutions, media and serum were all 
obtained from Gibco (Invitrogen). 
 
3.2 Reagents  
5-aminolevulinic acid (Sigma Aldrich) stock solution (300 mM) was dissolved in water, 
filtered and stored at -20°C. The ABCG2 inhibitor Ko143
41,42 (Sigma Aldrich) stock solution 
(5 mM) was prepared by solving the powder in DMSO and store at -20°C. H2O2 (Sigma 
Aldrich) was pre-diluted in water (stock solution 1M) before utilized and stored at +4°C. 
Etoposide (Sigma Aldrich) stock solution (25μg/μl) was dissolved in DMSO and stored at -
20°C. The ATM inhibitor KU-55933 (Sigma Aldrich) stock solution (10mM) was prepared 
by dissolving the powder in DMSO and stored at -20°C. 
 
3.3 PDT treatment 
All photodynamic treatments performed throughout this work were carried out on cells as 
previously described by us and other Authors
43, 44
. All cells were incubated in the dark for 3 h 
in serum-free medium in the presence of an excess of 5-ALA (0.5 or 1.0 mM), aimed to 
obtain a greater amount of endogenous PpIX. After incubation, cells were washed 3 times 
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with Hank’s solution (Sigma Aldrich) and then exposed to light. In particular, PDT was 
administered to cells 72 (H1299 and A549) or 48 hours (HCT-116 (
+/+
 and 
-/-
) and PC3) after 
their seeding. Cells were irradiated using a LED array (S-630, Alpha Strumenti, Melzo, Italy) 
designed specifically for Photodynamic therapy. The light source was characterized by an 
emitting wavelength of 630 nm and an irradiance of 5 Jcm
-2
 per minute. The red-light source 
was placed at a distance from the plates to ensure uniform illumination of the entire cell 
monolayer. Light fluences used ranged from 0 to 20 Jcm
-2
. Before further analyses, irradiated 
cells were released into drug-free complete medium and kept in the incubator as required.  
 
3.4 Protoporphyrin IX measurements 
Determination of Protoporphiryn IX production was performed according to Wild et al.
45
. To 
this purpose ~1.0x10
5
 H1299 or A549 cells, ~3.0x10
5
 HCT-116 (
+/+
 and 
-/-
) cells and ~3.5x10
5
 
PC3 cells were seeded in 60-mm tissue culture dishes. All steps of these protocols were 
performed in the dark in order to avoid the photobleaching of Protoporphiryn IX. Cells were 
incubated without (relative controls) or with ALA (3 hs) in serum-free medium in the dark. 
Production of intracellular Protoporphiryn IX was measured in cells after their detaching (by 
mild trypsinization), washing in PBS, and collection by centrifugation (1200 rpm, 5 min). 
Cells were resuspended in 1:1 methanol (HPLC grade): perchloric acid (0.9M) and 
homogenized using an homogenizer (Ultra-Turrax T25-IKA Germany). The suspension was 
then centrifuged at maximum speed and surnatants quickly transferred into quartz cuvette for 
fluorescence measurements (emission spectra).  
Measurements were performed in Perkin-Elmer spectrofluorimeter setting the excitation 
wavelength at 406 nm and the excitation and emission slits at 10 nm. Fluorescence spectra 
were collected between 550 nm and 700 nm. 
 
3.5 Cell Viability Assays 
All cells were seeded in 35-mm tissue culture dishes (A549 and H1229, ~5.0 x 10
4
, HCT-116 
and PC3, ~1.2 x 10
5
) in triplicate and exposed to PDT as indicated above. The difference in 
initial cell density is related to the individual different growth rate. In all cases, cell viability 
was evaluated by Trypan blue assay 24 hours after PDT. No significant changes in cell 
viability-light fluence dose-response curves were observed when PDT was administered to 
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cells incubated with 1.0 or 0.5 mM 5-ALA. However, since 1 mM 5-ALA resulted slightly 
toxic to PC3 cells even in the absence of light, the experiments with PC3 cells, reported 
therein, have been performed with the lower 5-ALA concentration (0.5 mM).  
Routinely, a solution of Trypan blue (Sigma Aldrich, St Louis USA)/trypsinized cell 
suspensions 1:10 was prepared. Subsequent experiments were performed on the basis of these 
dose responses curves as only two specific light fluences for each cell line were considered. In 
particular, we selected the 2 light fluences that induce ~25% or ~50% cell death in each cell 
line. From the dose response curves the fluences used were 6 and 12 Jcm
-2
 for H1299, 4 and 8 
Jcm
-2
 for A549, 7.5 and 15 Jcm
-2
 for HCT-116 
+/+
, 10 and 20 Jcm
-2
 for HCT-116 
-/-
, 5 and 10 
Jcm
-2
 for PC3 cells, respectively. This kind of selection allowed us to consider the different 
cells in conditions that determine, independently from the cell line used, the same reduction of 
viability. Residual viability was expressed as percentage (mean ± SD) of trypan blue–negative 
cells versus untreated controls.  
 
3.6 Cell cycle analysis  
Cells (~1.0 x 10
5
 H1299 and A549, ~3.0 x 10
5
 HCT-116, and ~3.5 x 10
5
 PC3) were seeded in 
60-mm tissue culture dishes in triplicate and exposed to PDT as detailed in the section 3.3. As 
stated before, only two fluences were chosen for each cell line, namely 6 and 12 Jcm
-2
 for 
H1299, 4 and 8 Jcm
-2
 for A549 cells, 10 and 20 Jcm
-2
 for HCT-116 
-/-
, 7.5 and 15 Jcm
-2
 for 
HCT-116 
+/+
, 5 and 10 Jcm
-2
 for PC3 cells. Six hours after PDT, cells were detached by 
trypsinization, washed in PBS, and fixed in 70% ethanol. Before analysis, cells were washed 
in PBS, resuspended in a PBS solution containing RNase (Roche) and propidium iodide 
(Sigma Aldrich), and stored in the dark for 20 min at RT. Fluorescence was detected using the 
488 nm laser line with a CyAn ADP Flow Cytometer (DAKO Cytomation, Milan, Italy). Not 
less than 20000 events (≥ 15000 cells) were recorded for each sample. Cell cycle profiles 
were analyzed using ModFit/LT 3.2 version (Verity Software, Topsham, ME, USA). Data 
were obtained from three independent experiments (triplicate samples) and expressed as mean 
± SD. 
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3.7 Alkaline Comet assays  
Cells were dealt exactly as for cell-cycle analysis (see above). Six hours after PDT, were 
detached by trypsinization, washed once with PBS, centrifuged and resuspended in PBS (1.0 
x 10
5
 cells/ml). Alkaline comet assay was performed according to the instructions provided by 
the kit manufacturer (Trevigen, Helgerman, CT, USA). Cells were combined with molten low 
melting Agarose (at 37°C) and pipetted onto CometSlide™. Slides were incubated at 4°C for 
20 min in the dark for the agarose to gel and the sample became adherent to the slide. Slides 
were then immersed in pre-chilled lysis solution for 45 min and subsequently in alkaline 
unwinding solution for 45 min in the dark. Slides were transferred in a horizontal 
electrophoresis apparatus (30 min, 1 V/cm, 300 mA), covered with alkaline electrophoresis 
solution, washed twice with H2O, incubated in ethanol for 5 min, air dried, stained with 
SYBR
TM
 Green and analyzed by fluorescence microscopy. For each sample more than 100 
cells were collected. Only undamaged DNA retains round shape, while damaged DNA 
migrates away from the nucleus, depending on the molecular weight of its fragments, 
acquiring the characteristic comet shape. Cell images were analyzed using COMET Score
TM
 
(TriTek, Annandale, VA, USA) to quantify DNA damage through measurements of the 
Comet tail moment, Olive moment and % DNA tail
46
. The fluorescence (arbitrary units) of 
tail moment, olive moment and % DNA tail has been reported as function of applied light 
fluences (mean ± SD). 
 
3.8 Histone H2AX phosphorylation assays 
Cells, dealt with as for cell-cycle analysis (see above), were washed (3 times) with a colorless 
Hank’s solution (Sigma Aldrich, St Louis USA), irradiated and released in fresh complete 
culture medium for 6h, detached with trypsin, centrifuged, washed with PBS (twice), and re-
suspended in 70% ethanol. To detect γ-H2AX, cells were incubated with anti-γ-H2AX 
(ser139) monoclonal antibody (Upstate) in 4% FBS TBS-T 0.1% for 2h at RT. Cells were 
washed with TBS-T 0,1% and incubated with a fluorescein-tagged anti-mouse secondary 
antibody (Sigma Aldrich, St Louis USA) in 4% FBS TBS-T 0.1% for 1h at RT in the dark. 
After washing with TBS-T 0.1%, cells were resuspended in TBS then analyzed in a CyAn 
ADP Flow Cytometer (DAKOCytomation) equipped with an excitation laser line at 488 nm. 
The data collected were analyzed using the Dako Summit Software version 4.3. The observed 
shift of the fluorescence signal (referred to the curve mean) was referred to the position in the 
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untreated control and expressed as percent (mean ± SD). About 20000 events (i.e., 
fluorescence readings, corresponding to not less than 15,000 cells) were recorded for each 
sample (triplicates). 
 
3.9 ABCG2 inhibition 
To induce ABCG2 protein inhibition, A549 and PC3 cells were treated with 1.5 and 2.0 µM 
Ko143 respectively
30
. The inhibitor has been added to the culture medium together with ALA 
in serum-free medium and then is re-added in the complete culture medium after light 
irradiation, until cells are harvested and analyzed. Although Ko143 has been considered a 
specific inhibitor of ABCG2, at high concentrations
42
 it inhibits also ABCB1 and ABCC1. In 
this work Ko143 concentration used was ≤ 2.0 µM42, 47 . Under these conditions (detailed in 
the respective figure legends), Ko143 inhibits specifically ABCG2. 
 
3.10 PpIX intracellular localization 
H1299 (1.0 x 10
5
) and PC3 (3.5 x 10
5
) cells were grown onto glass coverslips, allowed to 
adhere, then exposed to PDT; fluences used were 6 and 10 Jcm
-2 
for H1299 and PC3 cells, 
respectively. After irradiation the cells were washed with PBS, fixed and analyzed at time 0 h, 
or released in fresh culture medium and analyzed 6 h later. Cells treated with 5-ALA and did 
not irradiate (controls) were processed and analyzed at the same times of the irradiated ones. 
Cells were fixed in PBS/4% formaldehyde for 10 min in the dark. After further washes with 
PBS, samples were mounted and viewed with an LSM 710 inverted confocal laser-scanning 
microscope (Zeiss). 
 
3.11 Western blot analysis 
ABCG2 detection after PDT: Appropriate quantities of protein extracts were obtained from 
the following cell numbers: ~1.0 x 10
5
 H1299 or A549; ~3.0 x 10
5
 HCT-116 or PC3; exposed 
to the following fluences: 6 and 12 Jcm
-2 
for H1299; 4 and 8 Jcm
-2 
for A549; 10 and 20 Jcm
-2
 
for HCT-116 
-/-
; 7.5 and 15 Jcm
-2
 for HCT-116 
+/+
; and 5 and 10 Jcm
-2
 for PC3 cells. 
Cells were harvested 0.5, 1, 3 and 6 hours after PDT. Cellular pellets were suspended in lysis 
buffer; the proteins extracted were measured as previously reported
48, 49
. Polyacrylamide gels 
(stacking gel: 4% acrylamide, running gel:10% acrylamide) were prepared as described by 
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Laemmli
50
. Proteins separated on polyacrylamide gels were blotted onto nitrocellulose filters 
(Perkin Elmer). Molecular weight standards were from Fermentas Life Sciences (M-Medical, 
Milan, Italy). Filters were washed in PBS-T 0.1%, soaked in 5% non-fat dry milk in PBS-T 
0.1%, incubated with specific primary antibodies and then with secondary antibodies (Santa 
Cruz) conjugated to horseradish peroxidase (BioRad). The primary antibody against ABCG2 
was from Santa Cruz (CA, USA); anti-tubulin was provided by ABM (Richmond BC, 
Canada). Finally filters were developed using an electro-chemiluminescent western blotting 
detection reagent (Roche). 
ABCG2 detection on PC3 after treatment with H2O2 or Etoposide: Appropriate quantities of 
protein extracts were obtained from ~3.5 x 10
5
 PC3 cells. After 48 hours, cells were incubated 
with 1 mM H2O2 and then harvested 0.5, 1 and 3 hours later or 25 ng/μl of Etoposide in 
serum-free medium and then harvested 0.5, 1 and 4 hours later. Cellular pellets were treated 
and analyzed as reported above. 
 
3.12 RNA extraction, cDNA synthesis and RT-PCR  
For mRNA expression, ~3.5 x 10
5
 PC3 cells were seeded in 60-mm tissue culture dishes and 
then treated after 48 hours. For single treatment with Etoposide, cells were treated as 
indicated above. For combined treatment with KU-55933, cells were first pre-treated with 10 
μM in serum-free medium with the ATM inhibitor and then treated with Etoposide as above. 
Total RNA was extracted using Trizol (Gibco, Invitrogen) 0.5, 1 and 4 hours later for single 
treatment or 0.5 and 1 hour later last treatment for the combined one. Samples were quantized 
with NanoDrop 2000c (Thermo Fisher Scientific, Life technologies). RNA (1g) was reverse 
transcribed (RT) using a high-capacity reverse transcriptase kit (SensFAST cDNA Synthesis 
Kit, Bioline) according to manufacturer’s instructions. The mRNA level (50 ng for each 
cDNA) of ABCG2 was measured by on a StepOnePlus on DNA template (RT-PCR) System 
(Applied Biosystems) using the SYBR Green-detection system (Biorad) according to 
manufacturer's instructions. Following primers were used for ABCG2 cDNA amplification: 
(ABCG2 FW) 5’-AGC AGC AGG TCA GAG TGT GGT-3’ and (ABCG2 RV) 5’-TGC ATT 
GAG TCC TGG GCA GAA GT-3’. The levels of the housekeeping 18S transcript were used 
as a control for equal cDNA loading: (18S FW) 5’-GCG CTA CAC TGA CTG GCT C-3’ and 
(18S RV) 5’-CAT CCA ATC GGT AGT AGC GAC-3’. The thermal protocol was: 95° for 5 
sec, 95° for 15 sec, 55° for 20 sec, 72° for 30 sec (40 cycles), 95° for 5 sec, 65° for 1 min 
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(melting curves); reaction was stopped at 4°C. Calculations of relative expression levels were 
performed using the 2
−ΔΔCt
 method
51
 and take into account the values of at least two 
independent experiments performed in triplicate. 
 
3.13 Statistical analysis 
Significance was assessed using unpaired Student’s t test for comparison between two means 
(P values: *<0.05; **<0.01; ***<0.001). 
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4. RESULTS 
4.1 5-ALA/PDT AFFECTS CELL VIABILITY. 
To evaluate whether p53 had a role in protecting cells from the effect of photodynamic 
therapy we analyzed cell lines expressing p53 (A549 and HCT-116
+/+
) and cells constitutively 
p53 null or knock out derivatives (H1299, PC3 and HCT-116
-/- 
respectively). All cell lines 
analyzed are able to uptake exogenous 5-ALA, independently of the status of p53. 5-ALA is 
metabolically converted into the photosensitizer PpIX, as indicated by the characteristic shape 
of fluorescence spectra peaking at 604 nm and 670 nm (FIGURE 8). 
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FIGURE 8. Fluorescence emission spectra of PpIX in the five cell lines analyzed. 
Cells viability was assessed by Trypan blue assay. Cells were incubated with 5-ALA for 3 
hours and then irradiated with increasing doses of light. The assay has been performed 24 
hours after the release into drug-free complete medium (FIGURE 9). 
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FIGURE 9. Residual cell viability assessed by Trypan blue assay. Cells viability of A549, HCT-116
+/+
, H1299, 
HCT-116
-/-
 and PC3 are expressed as percentage of untreated controls in function of light fluence. Each bar is the 
average of triplicate measurements (mean±SD). Statistical significance (relative to control): 
*
P <0.05; 
**
P <0.01; 
***
P <0.001. 
5-ALA/PDT affects cellular viability in all cell lines tested in a light-dose dependent manner. 
PDT response is remarkably similar in all cell lines, regardless of p53 expression. In order to 
compare the different cell lines, subsequent experiments were performed using only two light 
fluences for each cell line which induce ~25% or ~50% cell death. Chosen fluences were: 6 
and 12 Jcm
-2
 for H1299, 4 and 8 Jcm
-2
 for A549, 7.5 and 15 Jcm
-2
 for HCT-116
+/+
, 10 and 20 
Jcm
-2
 for HCT-116
-/-
, 5 and 10 Jcm
-2
 for PC3 cells. 
 
 
4.2 5-ALA/PDT CAUSES CELL CYCLE ALTERATIONS 
To evaluate whether 5-ALA/PDT has a potential effect on cell cycle profiles, we performed a 
cytofluorimetric analysis. All cell lines were irradiated using the conditions already discussed 
and cell cycle profiles were collected 6 hours after PDT. 
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A549 (p53
+/+
) and PC3 (p53
-/-
) do not present significant alterations of the cell cycle profiles, 
which are very similar to the respective controls (FIGURE 10). 
 
FIGURE 10. Cell cycle profiles of A549 and PC3 cell lines. Cytofluorimetric assay were performed 6 hours 
after PDT in A549 and PC3 cell lines. The figure reported representative cell cycle profiles. Numerical data of 
the phase cycle reported under the various panels are the average of triplicate measurements (mean±SD). 
Statistical significance (relative to control): 
*
P <0.05; 
**
P <0.01; 
***
P <0.001. 
By contrast, the other cell lines (H1299 and both clones of HCT-116) display significant 
alterations of the cell cycle (FIGURE 11). 
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FIGURE 11. Cell cycle profiles of H1299 and HCT-116 (both clones). Cytofluorimetric assay were performed 
6 hours after PDT in H1299, HCT-116
+/+
 and HCT-116
-/-
 cell lines. The figure reported representative cell cycle 
profiles. Numerical data of the phase cycle reported under the various panels are the average of triplicate 
measurements (mean±SD). Statistical significance (relative to control): 
*
P <0.05; 
**
P <0.01; 
***
P <0.001. 
In H1299 cells 5-ALA/PDT determines a significant arrest of cells in S phase, which 
increases with the dose of light applied (FIGURE 11, upper panel). 
On the other hand, also HCT-116
+/+ 
cells display cell cycle alterations. Cell cycle arrest 
interests the G2 phase and it is also dependent on the dose of light applied (FIGURE 11, middle 
panel). 
Equally significant cell population shifts occur in HCT-116
-/-
 : at the lower dose of light these 
cells arrest essentially in G2 phase while, at higher light doses the cells arrest in S phase 
(FIGURE 11, lower panel). 
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PpIX and consequently ROS propagation reached the nuclear compartment in H1299 and 
HCT116 cell lines. A549 and PC3 did not show significant cell cycle alterations. These data 
suggest that 5-ALA/PDT can cause DNA damage in sensitive cell lines. 
 
 
4.3 CELL CYCLE ALTERATIONS CORRELATE WITH γ-H2AX HISTONE 
PHOSPHORYLATION 
To test the hypothesis that 5-ALA/PDT induces DNA damage in sensitive cell lines, we 
performed cytofluorimetric analysis to evaluate the PDT-induced accumulation of 
phosphorylated γ-H2AX histone. Phospho-γ-H2AX is phosphorylated by the checkpoint 
kinase ATM and marks double strand DNA breaks).
52, 53
 
Cells were treated and irradiated as indicated above and successively analyzed (6 hours after 
irradiation) to measure the levels of γ-H2AX phosphorylation on Ser139 (FIGURE 12). 
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FIGURE 12. γ-H2AX phosphorilation status after 5-ALA/PDT. Cytofluorimetric evaluation of γ-H2AX 
phosphorilation on Ser139 6 hours after PDT. Cells were grouped on the bases of the presence/absence of 
significant fluorescent shift. Phosphorylation levels are expressed as percentage of untreated controls. Each bar 
is the average of triplicate measurements (mean±SD). Statistical significance (relative to control): 
*
P <0.05; 
**
P 
<0.01; 
***
P <0.001. 
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Phospho- γ-H2AX accumulates upon PDT in the DNA of same cell lines that present cell 
cycle alterations (FIGURE 12). A549 and PC3 do not show any accumulation of phospho γ-
H2AX at any dose of light. Accumulation of phospho-γ-H2AX is in all cases light–dependent. 
On the other hand, treatment with 5-ALA by itself does not induce γ-H2AX histone 
activation.  
p53 status is not associated with light-induced DNA damage. In fact, both HCT116 lines 
(p53
+/+
 and p53
-/-
) and PC3 (p53
-/-
) cell lines showed slight fluence-dependent phospho-γ-
H2AX phosphorylation levels. Thus, p53 does not appear to be sufficient to protect nuclear 
DNA damage from PDT. 
 
 
4.4 5-ALA/PDT INDUCES DNA DAMAGE IN H1299 AND HCT-116 CELL 
LINES 
To strengthen the evidence of DNA damage in cell lines exposed to PDT, we decided to 
perform a Single Cell Gel Electrophoresis, otherwise known as “Comet Assay” because is 
considered a pivotal method to assess DNA damage. This assay exploits the property of DNA 
to maintain its integrity during an electrophoresis migration if it is not perturbed. Conversely, 
breaks in its structure make it free to migrate. DNA fragments assume the shape of the “tails” 
of the rounded “heads”; hence the formation of a “comet”. The extent of DNA breaks reflect 
the proportion of DNA that moves into the tail. Comet Assay is analyzed by three parameters: 
“tail moment”, “% DNA tail mean”, and “olive moment mean”. The “tail moment” is a 
parameter that takes into account DNA migration and the relative amount of DNA in the tail. 
The “% of DNA tail” quantifies the ratio between the fluorescence intensity of the head and 
tail (in a range from 0 to 100%). The “olive tail moment” is an index generated by the product 
of the tail length multiplied the % tail DNA.
46
 
Alkaline Comet Assay was performed under the same experimental conditions indicated 
above. Irradiated H1299 and HCT-116 cells display the comets and comet length’s tail 
increases with the light dose (FIGURE 13) as indicated also by the increase of the DNA tail, 
tail moment and olive moment. 
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FIGURE 13. Comet Assay for H1299, HCT-116
+/+
 and HCT-116
-/- 
cell lines. Comets images collected at 6 hs 
after PDT treatment through COMET ScoreTM software (TriTek Corp.) for H1299, HCT-116
+/+
 and HCT-116
-/-
 
cells (panels a, e and i, respectively). Tail moment mean (a. u.) as function of light fluence (panels b, f, j, 
respectively). for H1299, HCT-116
+/+
 and HCT-116
-/-
 cells. Percentage of DNA tail (a. u.) as function of light 
fluence for H1299, HCT-116
+/+
 and HCT-116
-/-
cells (panels c, g and k, respectively). Olive moment (a. u.) as 
function of light fluence for H1299, HCT-116
+/+
 and HCT-116
-/-
cells (panels d, h and l, respectively). Each point 
represents the fluorescence of > 100 cells (mean ± SD). Statistical signiﬁcance (in respect to control) P values: * 
< 0.05, ** < 0.01, *** < 0.001. 
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The comet assay performed in A549 and PC3 cells did not show any significant alteration 
(FIGURE 14). Irradiated cells maintain their rounded shape if compared to the controls, without 
any appreciable variation of the parameters analyzed. 
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FIGURE 14. Comet Assay for A549 and PC3 cell lines. Comet images collected at 6 hs after PDT treatment 
through COMET ScoreTM software (TriTek Corp.) for A549 and PC3 cells (panels a and e, respectively). Tail 
moment (a. u.) as function of light fluence for A549 and PC3 cells (panels b and f, respectively). Percentage of 
DNA tail (a. u.) as function of light fluence for A549 and PC3 cells (panels c and g, respectively). Olive moment 
(a. u.) as function of light fluence for A549 and PC3 cells (panels d and h, respectively). Each point represents 
the fluorescence of > 100 cells (mean ± SD). Statistical signiﬁcance (in respect to control) P values: * < 0.05, ** 
< 0.01, *** < 0.001. 
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4.5 DNA DAMAGE INVERSELY CORRELATES WITH THE LEVELS OF ABCG2 
TRANSPORTER 
It is known that ABCG2 (the ATP-binding cassette (ABC) transporter G2) has a role in 
regulating cellular accumulation of PpIX (and, more in general, porphyrin derivatives) in 
several cancer cells
32
. Hence, its ability to extrude PpIX could affect the response of cells to 
PDT.  
We analyzed the expression of ABCG2 in all cell lines before and after 5-ALA/PDT at 
different times. As reported in FIGURE 15, the five cells lines present different levels of the 
transporter and they can be sub-divided into lower and higher ABCG2 producers. 
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FIGURE 15. Expression profile of ABCG2. All cell lines have been schematized according to the 
presence/absence of ABCG2. Western Blot analyses were performed at 0.5, 1, 3 and 6 hs after PDT treatment. 
Tubulin was used as loading control. 
H1299 and HCT-116 contain low levels of ABCG2 protein (FIGURE 15, right panels) and 
accumulate DNA damage after light exposure. Conversely, A549 and PC3 contain high levels 
of ABCG2, which oscillate during the period of time after treatment (FIGURE 15, left panels) 
and present low levels of DNA damage 
47, 54, 55
. 
γ-H2AX histone activation (FIGURE 12) and Comet assay (FIGURE 13 AND 14) suggest that 
there is an inverse relationship between ABCG2 transporter levels and DNA damage PDT 
mediated. In fact, A549 and PC3, containing high levels of the transporter are resistant to 
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PDT-induced DNA damage. On the other hand, H1299 and HCT116 containing low ABCG2 
levels accumulate a significant DNA damage after PDT. 
 
 
4.6 PPIX REACHES NUCLEAR COMPARTMENT IN THE ABSENCE OF ABCG2. 
To induce DNA damage, PpIX must localize nearby the nucleus during irradiation to 
propagate ROS and oxidation products immediately after irradiation to the DNA. We have 
hypothesized that, in the absence of ABCG2, PpIX reaches the perinuclear area and mediates 
light-dependent damage. When ABCG2 is present, PpIX is extruded rapidly and DNA cannot 
be damaged by photoactivation.  
To validate this hypothesis, we decided to visualize the localization of PpIX in cells treated 
with 5-ALA by exploiting the spontaneous fluorescence of PpIX. Confocal microscopy 
analysis was performed in H1299 (p53
-/-
; low ABCG2) and PC3 (p53
-/-
;
 
high ABCG2) to 
measure intracellular PS (FIGURE 16). 
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FIGURE 16. PpIX distribution in H1299 and PC3 cell lines, with and without Ko143. Confocal microscopy 
of H1299 cells (panels a and b) and PC3 cells (panels c-f) after incubation with 5-ALA and, where indicated, 6 
hours after irradiation. PpIX is revealed by the red fluorescence (more details in the text). 
Both cell lines were irradiated at the highest light dose (6 and 10 Jcm
-2
, respectively) and 
analyzed immediately after incubation with 5-ALA or 6 hours later after PDT.  
After incubation with 5-ALA, H1299 shows PpIX mostly localized in the cytoplasm and in 
the perinuclear area, while, 6 hours later, the fluorescence slowly disappeared (FIGURE 16, 
panel a). Immediately after irradiation, PpIX localization is not altered. Conversely, 6 hours 
after irradiation (concomitant with DNA damage) PpIX fluorescence is detected in the nuclear 
area (FIGURE 16, panel b). Also in PC3 cells PpIX localizes in the cytoplasm and in the 
perinuclear region after 5-ALA incubation and, similarly to H1299, 6 hours later the 
fluorescence signal disappears (FIGURE 16, panel c). PC3 cells differ significantly from 
H1299 6 hours after irradiation. In fact, at this time, PpIX fluorescence is not detectable 
(FIGURE 16, panel d) and DNA damage is not present. One important difference between the 
two cell lines is the presence of significant levels of ABCG2. To demonstrate a direct 
involvement of ABCG2 in DNA damage after PDT, we used an ATP-binding cassette 
inhibitor namely Ko143 which, at concentrations below 1 μM, selectively inhibits ABCG2.42 
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Incubation of the cells with Ko143 maintains the PpIX fluorescence signal inside the cells 
after incubation with 5-ALA up to six hours (FIGURE 16, panel e). Moreover, after PDT in 
inhibitor-treated cells, PpIX fluorescence labels the perinuclear area (FIGURE 16, panel f). 
These data indicate that inhibition of ABCG2 results in cytoplasmic and, eventually, nuclear 
localization of PpIX. As an indirect sign of DNA damage, six hours after PDT, the cells 
change morphology and acquire a rounded shape, which is a sign of stress. Conversely, in 
control cells (not treated with Ko143) the fluorescence signal rapidly disappears resulting in 
resistance to light-induced DNA damage. As expected, in cells expressing very low levels of 
ABCG2, such as H1299, Ko143 did not modify PpIX fluorescence (data not shown). 
 
 
4.7 DNA DAMAGE OCCURS IN ABCG2 POSITIVE CELL LINES IN PRESENCE OF 
THE INHIBITOR KO143  
The above experiments indicate that the localization of PpIX in the perinuclear area is 
essential for DNA damage induced by PDT. Inhibition of ABCG2 prevents PpIX extrusion 
from the cells causing more efficiency cell death by PDT, due to high levels of PS that can re-
localized in the nuclear compartment. Under these conditions, PDT-resistant cells should 
become sensitive to light induced cell death. To demonstrate that ABCG2 is involved in PDT 
cell death resistance, we performed a Comet Assay in A549 and PC3 cells in the presence of 
Ko143 (FIGURE 17). 
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FIGURE 17. Comet assay for A549 and PC3 cells after treatment with Ko143. Comets images collected at 6 
hs after PDT treatment in the presence of Ko143 through COMET ScoreTM software (TriTek Corp.) for A549 
and PC3 cells (panels a and e, respectively). Tail moment (a. u.) as function of light fluence for A549 and PC3 
cells (panels b and f, respectively). Percentage of DNA tail (a. u.) as function of light fluence for A549 and PC3 
cells (panels c and g, respectively). Olive moment (a. u.) as function of light fluence for A549 and PC3 cells 
(panels d and h, respectively). Each point represents the fluorescence of > 100 cells (mean ± SD). Statistical 
signiﬁcance (in respect to control) P values: * < 0.05, ** < 0.01, *** < 0.001. 
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A549 and PC3 cells show a significant increase of the number and size of comets when 
exposed to PDT. Moreover, under these conditions there was a significant increase of tail 
moment, of % DNA tail and of olive moment (FIGURE 17, panels b-d and f-h). 
These data indicate that ABCG2 activity mediates the resistance to DNA damage PDT-
mediated. 
 
 
4.8 DNA DAMAGE INDUCES ABCG2 
Our data indicate that ABCG2 transporter levels increase after stress (5-ALA/PDT) but it is 
still unknown whether its expression depends on the ROS generated after irradiation or on the 
increased levels of PpIX per se. 
To unravel the mechanism(s) underlying ABCG2 induction, we first investigate whether 
ABCG2 levels are induced by ROS produced by H2O2
56
. To this end, we selected PC3 cell 
lines (p53
-/-
) to eliminate the contribution of p53 in stress-response regulation (FIGURE 18). 
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FIGURE 18. ABCG2 expression in PC3 after treatment with H2O2. Panel a: Western Blot analyses were 
performed at 0.5, 1 and 3 hs after H2O2 treatment. Tubulin was used as loading control. Panel b: Relative 
densitometry of the Western Blot. 
ROS produced stimulate ABCG2 protein levels and replicate the timing of the induction by 
PDT. We next tested whether DNA damage may affect ABCG2 expression levels. To this end 
we measured ABCG2 levels in cells exposed to Etoposide, a selective inhibitor of 
topoisomerase II enzyme that is able to induce DNA damage
57
 (FIGURE 19). 
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FIGURE 19. ABCG2 expression levels in PC3 after treatment with Etoposide. Panel a: Western Blot analyses 
were performed at 0.5, 1 and 4 hs after treatment with Etoposide. Tubulin was used as loading control. Panel b: 
mRNA level of ABCG2 normalized to 18S. Data points represent the average of triplicate determinations 
(media±SD). Statistical signiﬁcance (in respect to control) P values: ** < 0.01, *** < 0.001. 
ABCG2 protein levels increase in a dose and time dependent manner after DNA damage 
induced by Etoposide (FIGURE 19, panel a) suggesting that also its mRNA levels could 
increase after DNA damage. To test this point, we performed a RT-PCR on total RNA under 
the same conditions and we observed that the ABCG2 mRNA levels correlate with the protein 
levels (FIGURE 19, panel b). Since the major sensor of DNA damage is ATM, the 
serine/threonine protein kinase that is activated by DNA double-strand breaks
58, 59
, we tested 
the effects of the ATM inhibitor namely KU-55933
60
 on ABCG2 mRNA and protein levels. 
FIGURE 20 shows that ABCG2 mRNA levels were not induced by etoposide in the presence of 
the ATM inhibitor. These data show that ATM induced by DNA damage increases ABCG2 
levels. 
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FIGURE 20. ABCG2 expression levels in PC3 after treatment with KU-55399 and Etoposide. mRNA level of 
ABCG2 normalized to 18S after treatment with Etoposide alone or with a pretreatment with KU-55399 Data 
points represent the average of triplicate determinations (media±SD). Statistical signiﬁcance (in respect to 
control) P values: * < 0.05; ** < 0.01. 
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5. DISCUSSION 
In this work, we analyze the molecular mechanism of the signals induced by 5-ALA/PDT 
leading to cell death by using several cell lines, with or without p53. The effects we describe 
are not dependent on p53 status, although stress response and DNA damage are tightly 
controlled by p53. 
 
5.1 P53 STATUS DOES NOT AFFECT PDT-INDUCED CELL DEATH 
In both cell lines mentioned above, 5-ALA/PDT is able to reduce cell viability. Although 
A549 cell line (p53
+/+
) required lower doses of light fluences compared to H1299 (p53
-/-
) to 
succumb, cell cycle profiles of A549 cells surviving 5-ALA/PDT were almost unaffected. By 
contrast, significant alterations of cell cycle profile were present in H1299 (p53
-/-
) cell line, 
where is evident that cells succeeded in escaping G1 phase but stopped cycling because were 
arrested in S phase. The two cell line are both NSCLC cell lines and differ only for p53 status. 
These data suggest that the presence or the absence of p53 may be relevant. In fact, in A549, 
p53 may promote a cell cycle arrest in order to repair DNA, damaged by PDT. This does not 
happen in H1299 due to loss of p53. To prove that p53 was responsible of such different 
responses, we analyzed two other cell lines that differ for p53 status. We selected two clones 
derived from the same cell line, HCT116 wild type (p53
+/+
) and its counterpart HCT-116  
p53
-/-
 (knock out). As for the first two cell lines, 5-ALA/PDT affected cell viability and HCT-
116 (p53
-/-
) required higher light doses to undergo death. However, both cell lines present cell 
cycle alterations, independently of p53 status, suggesting that p53 status does not profoundly 
influence the sensitivity or resistance to PDT. In order to confirm such hypothesis, we 
selected a fifth cell line, PC3 cells, constitutively p53 null. This cell line shows, after 5-
ALA/PDT, the same behavior of A549, that are, conversely, p53 positive. 
Cell cycle alterations are strong signs of DNA damage than it is possible that 5-ALA/PDT, in 
more sensitive cell line, can be able to cause DNA damage. In order to confirm the nuclear 
involvement, we analyzed directly an important mark of DNA damage, phospho-γ-H2AX. 
We assessed the levels of phosphorylation of serine 139 in γ-H2AX histone (cytofluorimetry) 
and the formation of comets (comet assays), both indicators of DNA damage and replication 
stress
46, 52, 53
. In cells that show cell cycle profile alterations, H1299 and HCT-116 cell lines 
(p53
+/+
 and p53
-/-
), there is also an increase in the phosphorylation of histone γ-H2AX, a clear 
DISCUSSION 
36 
sign of the occurrence double strand breaks at a chromatinic level and then of activation of 
checkpoints proteins aimed to the cell cycle arrest and DNA repair. Also, the Comet Assay 
analysis showed the occurrence of DNA comets, further confirming the DNA damage PDT-
mediated. On the other hand, the two cell lines that did not present cell cycle alterations 
(A549 and PC3) showed no significant increase of γ-H2AX phosphorylation level and no 
comet formation, coherently with the absence of DNA damage and cell cycle alterations. 
 
These data demonstrate that 5-ALA/PDT is able to cause DNA damage in sensitive cell lines 
and that p53 status is not relevant for resistance or sensitivity to 5-ALA/PDT. 
 
 
5.2 ABCG2 ACTIVITY INDUCES RESISTANCE TO PDT 
DNA damage may be triggered by PpIX accumulation especially in the perinuclear region and 
it may be not significant in cells that rapidly remove PpIX from cytoplasm. PpIX 
accumulation is regulated by several factors that are involved in its uptake and metabolism or 
in the management of its intermediates and biosynthesis
61,
 
62
. Despite p53 status, all five cell 
lines are able to uptake and metabolize 5-ALA in PpIX. This is confirmed by its characteristic 
emission fluorescence spectrum and by confocal microscopy images collected. Thanks to 
PpIX spontaneous fluorescence, such images give also important information about its 
localization inside the cell before and after the treatment. 
Recently, it has been described that ATP binding cassette (ABC) transporters, in particular 
ABCG2, mediate not only the efflux of several drugs
33, 63
 but also PpIX, causing resistance to 
PDT
36
 and altering its outcome
32, 37
. ABCG2, extruding PpIX (and porphyrins in general
68
), 
confers cell resistance to several treatments and promotes cells survival during stress 
conditions. 
It is known that ABCG2 expression correlates with low PpIX accumulation after 5-ALA 
administration
47
 
64
. On the basis of such evidences, we decided to analyze the expression 
levels of ABCG2 in our five cell lines and we found that ABCG2 expression negatively 
correlates with DNA injury PDT-mediated. In fact, H1299 and both HCT116 clones express 
low level of this protein while A459 and PC3 (that do not show clear signs of DNA damage) 
express high levels of this membrane transporter. Some inhibitors of ABCG2 are known and, 
among these, Ko143 is considered a strong inhibitor (although not highly specific at high 
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concentrations) that promotes PpIX accumulation
47
. This inhibitor may be able to reverse the 
resistance of cells to 5-ALA/PDT. In fact, after the administration of Ko143 and 5-ALA/PDT 
exposure, A549 and PC3 cell lines show clear signs of DNA damage.  
To prove that, we compared the cellular PpIX localization in two cell lines, H1299 and PC3, 
that are p53
 
null, but differ with regard to ABCG2 expression. Both cell lines are able to 
internalize and metabolized 5-ALA to PpIX but PpIX distribution different because it 
appeared mostly perinuclear in H1299 (ABCG2 negative), and largely cytoplasmic in the PC3 
cells (ABCG2 positive). They also had operative extrusion systems for PpIX because the 
fluorescence emission became fade during the time, if not exposed to irradiation. The 
exposure to light produced different effects: the PC3 cells showed 6 hours later PDT a 
residual fluorescence in the cytoplasm; at variance, after 6 hours from irradiation, in the 
H1299 cells was still present an evident PpIX fluorescent signal. The different behavior could 
be attributed to the activity of ABCG2, because PC3 cells, treated with the inhibitor Ko143, 
become no more able to extrude PpIX outside the cell . 
 
On the basis of such evidences, we conclude that the resistance or the sensitivity of the cell 
lines indicated are dependent on the levels of ABCG2.  
 
 
5.3 ATM INDUCES ABCG2 
ABCG2, if inhibited or absent, amplifies DNA damage induced by 5-ALA/PDT, but it seems 
to be also activated by general DNA damage. Our experiments with KU-55399, the ATM 
inhibitor, or Etoposide, a drug that induces DNA damage and activates ATM, show clearly 
that ATM activates ABCG2 transcription because, when it is inhibited, it decreases ABCG2 
mRNA levels. ROS by them selves are not as efficient as Etoposide probably because the 
damage and ATM activation are limited. 
 
In conclusion, the data shown above identify a novel target to manipulate the resistance of 
cancer cells to PDT and suggest a mechanism of action underlying resistance of cells to a 
great variety of molecules used in chemotherapy. 
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6. CONCLUSIONS 
The data presented suggest that ABCG2 expression influences the response to 5-ALA/PDT 
induced damage. In fact when its activity was inhibited, DNA was damaged by PDT. When 
PpIX can accumulate non only in the cytoplasm but also in the perinuclear area because its 
extrusion is inhibited, the nucleus becomes more sensitive to ROS generated by PpIX 
photoactivation and DNA is more susceptible to injury. DNA damage is the final effect of 
ROS propagation since it occurs 6 hours after irradiation, a time frame sufficient for PpIX to 
re-localize within the cell when ABCG2 is inactive. 
The occurrence of DNA damage may represent an improvement for 5-ALA/PDT clinical 
applications. 
 
Taking together, the present observations not only provide new information on the 
effectiveness of 5-ALA/PDT but also indicate a potential way to shift PDT from a palliative 
to a more effective tool in cancer therapy 
Moreover, ABCG2 expression is induced not only by ROS, but also by DNA damage itself. 
In particular, its expression is enhanced by ATM activation since ATM inhibition reduces 
significantly ABCG2 levels. 
These data highlight a complex interaction between DNA damage checkpoints and ABCG2 
levels, which can be extended to other DNA damaging agents. 
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